Opendata, web and dolomites

CB-103

First effective targeted therapy for T-cell acute lymphoblastic leukemia (T-ALL) and other NOTCH pathway driven cancers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CB-103 project word cloud

Explore the words cloud of the CB-103 project. It provides you a very rough idea of what is the project "CB-103" about.

standard    reduce    too    breast    250    people    verifying    index    children    chain    commercialization    therapeutic    care    cell    model    75    issue    forms    rates    progression    roots    scalable    thanks    cellestia    toxicity    expansion    significantly    dose    stopping    business    killing    answer    stage    25    drugs    ineffective    adverse    treatment    supply    aggressive    lymphoblastic    planning    complete    cancers    dlt    strategy    aged    acute    indicate    103    trials    drug    cure    cells    improvement    inhibiting    collaborations    downstream    leukemia    marrow    off    limiting    total    blood    tumor    median    ones    cb    accounts    relative    found    stem    roles    healthy    transcription    prolongs    survival    compound    toxicological    drive    tumorigenesis    cancerous    bone    small       blocks    molecule    14    signaling    benefit    cancer    chemotherapy    discriminate    additionally    lung    clinical    play    oncogenic    dependent    colorectal    notch    afflicted    conventional    efficiency    activated    establishing   

Project "CB-103" data sheet

The following table provides information about the project.

Coordinator
CELLESTIA BIOTECH AG 

Organization address
address: HOCHBERGERSTRASSE 60 C
city: Basel
postcode: CH 4057
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.cellestia.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CELLESTIA BIOTECH AG CH (Basel) coordinator 50˙000.00

Map

 Project objective

T-cell Acute Lymphoblastic Leukemia (T-ALL) is an aggressive NOTCH-dependent cancer that affects the blood and bone marrow especially in children aged 0-14 years, and currently has no effective cure. T-ALL accounts for about 25% of the total cases of Lymphoblastic Leukemia (ALL); additionally, an estimated 250,000 people are afflicted by NOTCH-dependent cancers every year. Chemotherapy, the standard-of-care treatment for T-ALL, can reduce tumor growth, but it is ineffective at killing the cancer stem cells that drive tumor progression. Moreover, it can lead to adverse toxicological effects as a result of off-target toxicity, as the drug cannot discriminate between healthy and cancerous cells. Small molecule drugs help to solve this issue thanks to their high efficiency in targeting tumor cells. Cellestia may have found the answer. Its novel approach targets a tumor development pathway, the NOTCH, which play crucial oncogenic roles in tumorigenesis, tumor expansion and survival. By inhibiting the NOTCH signaling in its most downstream part, Cellestia’s small molecule compound, CB-103, blocks the problem at the roots (i.e. specifically at the level of the NOTCH transcription complex) stopping cancer cells growth and survival. Pre-clinical results show CB-103 to have a high therapeutic index relative to conventional cancer drugs. Most importantly, it significantly prolongs survival rates (median improvement of 75%) with no adverse side effects or dose-limiting toxicity (DLT). Results indicate it may have benefit for other cancers too – any in which NOTCH pathway is highly activated, including forms of leukemia and other cancers such as lung, breast and colorectal. The Phase 1 project will be focused on establishing a complete and scalable supply chain, verifying the business model and commercialization strategy, planning new collaborations and partnerships, including the ones to implement the next clinical trials stage.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CB-103" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CB-103" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

LTS (2020)

LEARNING TO SLEEP: INCREASING HEALTH THROUGH BETTER SLEEP

Read More